scholarly journals Synthesis and evaluation of novel tropane derivatives as potential PET imaging agents for the dopamine transporter

2012 ◽  
Vol 22 (13) ◽  
pp. 4303-4306 ◽  
Author(s):  
Hongwen Qiao ◽  
Lin Zhu ◽  
Brian P. Lieberman ◽  
Zhihao Zha ◽  
Karl Plössl ◽  
...  
Keyword(s):  
Dopamine Transporter ◽  
Pet Imaging ◽  
Imaging Agents ◽  
Tropane Derivatives

scholarly journals Synthesis and evaluation of novel N-fluoropyridyl derivatives of tropane as potential PET imaging agents for the dopamine transporter

2011 ◽  
Vol 21 (10) ◽  
pp. 2962-2965 ◽  
Author(s):  
Jingying Liu ◽  
Lin Zhu ◽  
Karl Plössl ◽  
Brian P. Lieberman ◽  
Hank F. Kung
Keyword(s):  
Dopamine Transporter ◽  
Pet Imaging ◽  
Imaging Agents ◽  
Derivatives Of

Altropane, a SPECT or PET imaging probe for dopamine neurons: I. dopamine transporter binding in primate brain

Synapse ◽  
1998 ◽  
Vol 29 (2) ◽  
pp. 93-104 ◽  
Author(s):  
Bertha K. Madras ◽  
Peter C. Meltzer ◽  
Anna Y. Liang ◽  
David R. Elmaleh ◽  
John Babich ◽  
...  
Keyword(s):  
Dopamine Transporter ◽  
Pet Imaging ◽  
Dopamine Neurons ◽  
Imaging Probe ◽  
Primate Brain

scholarly journals Dopamine transporter imaging in neurodegenerative movement disorders: PET vs. SPECT

2020 ◽  
Vol 8 (5) ◽  
pp. 349-356
Author(s):  
Vera S. Kerstens ◽  
A. Varrone
Keyword(s):  
Dopamine Transporter ◽  
Pet Imaging ◽  
Single Photon ◽  
Relevant Literature ◽  
Photon Emission ◽  
Active Role ◽  
Emission Computed Tomography ◽  
Parkinsonian Syndromes ◽  
Dat Spect

Abstract Purpose The dopamine transporter (DAT) serves as biomarker for parkinsonian syndromes. DAT can be measured in vivo with single-photon emission computed tomography (SPECT) and positron emission tomography (PET). DAT-SPECT is the current clinical molecular imaging standard. However, PET has advantages over SPECT measurements, and PET radioligands with the necessary properties for clinical applications are on the rise. Therefore, it is time to review the role of DAT imaging with SPECT compared to PET. Methods PubMed and Web of Science were searched for relevant literature of the previous 10 years. Four topics for comparison were used: diagnostic accuracy, quantitative accuracy, logistics, and flexibility. Results There are a few studies directly comparing DAT-PET and DAT-SPECT. PET and SPECT both perform well in discriminating neurodegenerative from non-neurodegenerative parkinsonism. Clinical DAT-PET imaging seems feasible only recently, thanks to simplified DAT assessments and better availability of PET radioligands and systems. The higher resolution of PET makes more comprehensive assessments of disease progression in the basal ganglia possible. Additionally, it has the possibility of multimodal target assessment. Conclusion DAT-SPECT is established for differentiating degenerative from non-degenerative parkinsonism. For further differentiation within neurodegenerative Parkinsonian syndromes, DAT-PET has essential benefits. Nowadays, because of wider availability of PET systems and radioligand production centers, and the possibility to use simplified quantification methods, DAT-PET imaging is feasible for clinical use. Therefore, DAT-PET needs to be considered for a more active role in the clinic to take a step forward to a more comprehensive understanding and assessment of Parkinson’s disease.

Synthesis and evaluation of pyridylbenzofuran, pyridylbenzothiazole and pyridylbenzoxazole derivatives as 18F-PET imaging agents for β-amyloid plaques

2012 ◽  
Vol 22 (13) ◽  
pp. 4332-4337 ◽  
Author(s):  
Britt-Marie Swahn ◽  
Johan Sandell ◽  
David Pyring ◽  
Margareta Bergh ◽  
Fredrik Jeppsson ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Amyloid Plaques ◽  
Imaging Agents ◽  
Β Amyloid

Synthesis of 2-R1-2-(4-(2-fluoroethoxy)benzamido)acetate as potential PET imaging agents

2011 ◽  
Vol 21 (6) ◽  
pp. 944-951 ◽  
Author(s):  
Yong He ◽  
Jingli Xu ◽  
Hang Liu ◽  
Man Feng ◽  
Xiao Wang ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Imaging Agents
Sign in / Sign up

Export Citation Format

Share Document